Related references
Note: Only part of the references are listed.Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
Christoph Schmid et al.
BONE MARROW TRANSPLANTATION (2022)
The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease
Amy B. Hont et al.
MOLECULAR THERAPY (2022)
Harnessing cytokines and chemokines for cancer therapy
David J. Propper et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Lukas Kraehenbuehl et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials
Jianming Tang et al.
VIRUSES-BASEL (2022)
Population Trends and Long-term Outlook for Oropharyngeal Cancer Have We Found a Silver Lining?
Nosayaba (Nosa) Osazuwa-Peters et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2022)
Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001-2017
Haluk Damgacioglu et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2022)
Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial
Rick Admiraal et al.
Lancet Haematology (2022)
From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guerin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
Susanne Deininger et al.
CANCERS (2022)
Engineering interferons and interleukins for cancer immunotherapy
Patrick G. Holder et al.
ADVANCED DRUG DELIVERY REVIEWS (2022)
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Jean-Jacques Kiladjian et al.
LEUKEMIA (2022)
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Smita S. Chandran et al.
NATURE MEDICINE (2022)
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
Yi-Wen Huang et al.
VIRUSES-BASEL (2022)
Radiolabeled Antibodies for Cancer Imaging and Therapy
Sagun Parakh et al.
CANCERS (2022)
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL
Zaid Al-Kadhimi et al.
BONE MARROW TRANSPLANTATION (2022)
Current state of play for HPV-positive oropharyngeal cancers
Fiona Deutsch et al.
CANCER TREATMENT REVIEWS (2022)
Efficacy of thymosin α1 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043)
Fangjie Liu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Paul G. Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
Luisa Chocarro et al.
CELLS (2022)
Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2022)
Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
Endeshaw Chekol Abebe et al.
FRONTIERS IN IMMUNOLOGY (2022)
Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
Yueshui Zhao et al.
CANCERS (2022)
Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers
Tobias Ettl et al.
CANCERS (2022)
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A. Boorjian et al.
LANCET ONCOLOGY (2021)
Hepatitis B Vaccines
Jade Pattyn et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Engineering IL-2 to Give New Life to T Cell Immunotherapy
Willem W. Overwijk et al.
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study
Milena Falcaro et al.
LANCET (2021)
Naxitamab: First Approval
Anthony Markham
DRUGS (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Penile cancer
Anita Thomas et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis
Kathryn E. Cole et al.
CELLULAR IMMUNOLOGY (2021)
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
Joel Guigay et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer
Susanne K. Kjaer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hani Babiker et al.
ONCOLOGIST (2021)
Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018
Hannah G. Rosenblum et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah et al.
LANCET (2021)
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
Stephen J. Schuster et al.
LANCET ONCOLOGY (2021)
Pembrolizumab use in bladder cancer: a tale of two trials
Jeanny B. Aragon-Ching
NATURE REVIEWS UROLOGY (2021)
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Hillard M. Lazarus et al.
FRONTIERS IN IMMUNOLOGY (2021)
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
Kedar Kirtane et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T
Tanya Dorff et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Bacillus Calmette-Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections
Emilie Stavnsbjerg Larsen et al.
APMIS (2020)
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival
Shawn Kothari et al.
BONE MARROW TRANSPLANTATION (2020)
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
Renjie Wang et al.
CANCER LETTERS (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
HPV vaccination and cancer prevention
A. Athanasiou et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2020)
A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer
Yasmin Hasan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pembrolizumab for the treatment of esophageal cancer
Shun Yamamoto et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
Markus Hecht et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cytokines in CAR T Cell-Associated Neurotoxicity
Juliane Gust et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials
Joanne M. Mankor et al.
EBIOMEDICINE (2020)
Biological and clinical aspects of HPV-related cancers
Klaudia Anna Szymonowicz et al.
CANCER BIOLOGY & MEDICINE (2020)
An update on GM-CSF and its potential role in melanoma management
O. Robert Dillman
MELANOMA MANAGEMENT (2020)
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Tanios Bekaii-Saab et al.
CLINICAL CANCER RESEARCH (2019)
Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis
Denis Claude Roy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Prostate Cancer, Version 2.2019
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity
Shuting Shi et al.
VACCINE (2019)
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Melanie Drolet et al.
LANCET (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
Celestia S. Higano et al.
CANCER (2019)
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Reappraisal of Thymosin Alpha1 in Cancer Therapy
Claudio Costantini et al.
FRONTIERS IN ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process
Emily L. Hopewell et al.
CYTOTHERAPY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Towards the global elimination of cervical cancer
Karen Canfell
PAPILLOMAVIRUS RESEARCH (2019)
BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection
Xueping Yu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
Kathleen L. Dooling et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
A. D. Colevas et al.
ANNALS OF ONCOLOGY (2018)
An Update on Immunotherapy for Solid Tumors: A Review
Toan Pham et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
D. E. Meyers et al.
CURRENT ONCOLOGY (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients
Wojciech Krajewski et al.
UROLOGIA INTERNATIONALIS (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Diwakar Davar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer immunotherapy sweeps Nobel for medicine Prize goes to discoveries that unleash immune system
Jocelyn Kaiser et al.
SCIENCE (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
CD4+ T cell help in cancer immunology and immunotherapy
Jannie Borst et al.
NATURE REVIEWS IMMUNOLOGY (2018)
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
Susanne K. Kjaer et al.
CLINICAL INFECTIOUS DISEASES (2018)
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Arnaud M. Didierlaurent et al.
EXPERT REVIEW OF VACCINES (2017)
HPV vaccines - A review of the first decade
Diane M. Harper et al.
GYNECOLOGIC ONCOLOGY (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
Lee Pai-Scherf et al.
ONCOLOGIST (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors
Emily A. Sloan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
Liver Inflammation and Cancer: The Role of Tissue Microenvironment in Generating the Tumor-Promoting Niche (TPN) in the Development of Hepatocellular Carcinoma
Eithan Galun
HEPATOLOGY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
Allan Hildesheim et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2016)
Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
M. Thorn et al.
CANCER GENE THERAPY (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience
Suzanne M. Garland et al.
CLINICAL INFECTIOUS DISEASES (2016)
Pembrolizumab in classical Hodgkin's lymphoma
Joseph Maly et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer
Elisabeth Brambilla et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Cosette M. Wheeler et al.
LANCET INFECTIOUS DISEASES (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
From Benchtop to Bedside: A Review of Oncolytic Virotherapy
Audrey H. Choi et al.
BIOMEDICINES (2016)
Thymosin α1 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1
Chao Yuan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Jason J. Luke et al.
ONCOTARGET (2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Luisa Carbognin et al.
PLOS ONE (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
Aaron P. Rapoport et al.
CLINICAL CANCER RESEARCH (2014)
Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
Maurizio Brausi et al.
EUROPEAN UROLOGY (2014)
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy
Denise Skrombolas et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Key role for myeloid cells: Phase II results of anti-GD2 antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma
Nai-Kong V. Cheung et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Andrea Schietinger et al.
TRENDS IN IMMUNOLOGY (2014)
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
Daniel E. Speiser et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
J. D. Wolchok et al.
ANNALS OF ONCOLOGY (2013)
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
Vafa Shahabi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica
Rolando Herrero et al.
PLOS ONE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naive Women in HPV Vaccine Trials
Mahboobeh Safaeian et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma Current Status and Future Outlook
Richard Wu et al.
CANCER JOURNAL (2012)
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells
Barbara Drobits et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor
Irene Y. Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
US Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma
Thomas M. Herndon et al.
ONCOLOGIST (2012)
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Grazia Graziani et al.
PHARMACOLOGICAL RESEARCH (2012)
Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
Claire Biot et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Trial watch FDA-approved Toll-like receptor agonists for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
Bladder Cancer Immunotherapy: BCG and Beyond
Eric J. Askeland et al.
ADVANCES IN UROLOGY (2012)
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial
Edward A. Stadtmauer et al.
BLOOD (2011)
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
Aaron P. Rapoport et al.
BLOOD (2011)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2011)
CpG DNA as a vaccine adjuvant
Christian Bode et al.
EXPERT REVIEW OF VACCINES (2011)
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer
Ravi A. Madan et al.
IMMUNOTHERAPY (2011)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Ipilimumab
Vernon K. Sondak et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dominant role of HPV16 E7 in anal carcinogenesis
Marie K. Thomas et al.
VIROLOGY (2011)
Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guérin (BCG) immunotherapy
A. M. JACKSON et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow af
Atif M. Hussein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL
Stephanie L. Goff et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Review of mifamurtide in the treatment of patients with osteosarcoma
Leo Kager et al.
Therapeutics and Clinical Risk Management (2010)
Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells
Aaron P. Rapoport et al.
CLINICAL CANCER RESEARCH (2009)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
Alum Induces Innate Immune Responses through Macrophage and Mast Cell Sensors, But These Sensors Are Not Required for Alum to Act As an Adjuvant for Specific Immunity
Amy S. McKee et al.
JOURNAL OF IMMUNOLOGY (2009)
AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
New horizons in adjuvants for vaccine development
Steven G. Reed et al.
TRENDS IN IMMUNOLOGY (2009)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The tumor microenvironment and its role in promoting tumor growth
T. L. Whiteside
ONCOGENE (2008)
Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and γδT cells
Michio Naoe et al.
INTERNATIONAL JOURNAL OF UROLOGY (2007)
GARDASIL®:: Prophylactic human papillomavirus vaccine development -: From bench top to bed-side
L. Shi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
High number of intraepithelial CD8(+) tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer
Sytse J. Piersma et al.
CANCER RESEARCH (2007)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Role of Th1-stimulating cytokines in bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells
Y. Luo et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion
Michael P. Schoen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
DL Porter et al.
BLOOD (2006)
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
AP Rapoport et al.
NATURE MEDICINE (2005)
Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis - Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials
N Korman et al.
ARCHIVES OF DERMATOLOGY (2005)
Negative regulation of T cell homeostasisby lymphocyte activation gene-3 (CD223)
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2005)
Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus Calmette-Guerin for superficial bladder tumors
M Eto et al.
UROLOGIA INTERNATIONALIS (2005)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies
J Geisse et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression
P Andius et al.
BJU INTERNATIONAL (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hernatopoietic cell transplantation
GG Laport et al.
BLOOD (2003)
A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival
O Shahin et al.
JOURNAL OF UROLOGY (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis
AN Persaud et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin
M Brake et al.
JOURNAL OF UROLOGY (2000)
Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study
TA Syed et al.
JOURNAL OF INFECTION (2000)
Share Paper
